Market Insights Health Pharmaceuticals Vaccines

COVID-19 Vaccines - Netherlands

Netherlands

The Netherlands is projected to witness a significant rise in revenue within the COVID-19 Vaccines market, reaching US$98.92m in 2024.
This growth is expected to continue with an annual growth rate (CAGR 2024-2028) of -20.94%, leading to a market volume of US$38.64m by 2028.
When compared globally, United States is forecasted to generate the highest revenue, amounting to US$1,832,000.00k in 2024.
Despite initial challenges, the Netherlands has made significant progress in the distribution and administration of COVID-19 vaccines, ensuring widespread coverage among its population.

Key regions: Japan, Italy, China, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Netherlands has been making steady progress in vaccinating its population against COVID-19. As of August 2021, over 70% of the adult population has received at least one dose of the vaccine. This has led to a significant decline in COVID-19 cases and hospitalizations in the country.

Customer preferences: The Dutch government has been providing COVID-19 vaccines for free to all residents and citizens. The majority of the population has shown willingness to get vaccinated, with only a small percentage being hesitant. The government has been actively promoting the benefits of getting vaccinated through various campaigns and incentives.

Trends in the market: The COVID-19 vaccine market in the Netherlands has been dominated by Pfizer-BioNTech, Moderna, and AstraZeneca. The government has also recently approved the use of the Johnson & Johnson vaccine. The demand for vaccines has been high, with many people eager to get vaccinated as soon as possible. The government has been ramping up its vaccination efforts to meet this demand.

Local special circumstances: The Netherlands has a highly developed healthcare system, which has helped in the efficient distribution and administration of vaccines. The country has also been working closely with the European Union to secure a steady supply of vaccines. However, the country has faced some challenges in the distribution of vaccines to its Caribbean territories, which are part of the Kingdom of the Netherlands.

Underlying macroeconomic factors: The Dutch economy has been severely impacted by the COVID-19 pandemic, with several industries facing significant losses. The government has been providing financial support to businesses and individuals affected by the pandemic. The successful vaccination campaign is expected to boost economic recovery, as it will allow for the easing of restrictions and the reopening of businesses.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.